We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Docetaxel-based combination therapy for castration-resistant prostate cancer.
- Authors
Galsky, M D; Vogelzang, N J
- Abstract
Once castration resistance is documented and secondary hormone therapy is ineffective, standard treatment of metastatic prostate cancer is docetaxel, with bisphosphonates and radiopharmaceuticals administered to treat bone symptoms. To improve outcomes, numerous studies have evaluated docetaxel in combination with other agents. Here, results for docetaxel-based combination therapy in castration-resistant prostate cancer (CRPC) are reviewed.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Vol 21, Issue 11, p2135
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdq050